Seung-Jea Tahk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seung-Jea Tahk has a total of 381 co-authors. Here are the top co-authors by number of shared publications:
- Hong-Seok Lim
Department of Cardiology Ajou University School of Medicine Suwon Republic of Korea
26 shared publications Joon-Han Shin
26 shared publicationsMyeong-Ho Yoon
Department of Cardiology, Ajou University School of Medicine, Suwon
26 shared publicationsSo-Yeon Choi
Department of Cardiology, Ajou University School of Medicine, Suwon
25 shared publications- Hyoung-Mo Yang
Department of Cardiology Ajou University School of Medicine Suwon Republic of Korea
23 shared publications Joon Han Shin
Department of Cardiology, Ajou University School of Medicine, Suwon, Korea
17 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Five‐Year Clinical Outcomes of Biodegradable Versus Durable Polymer Drug‐Eluting Stents: A Propensity Score‐Matched Analysis of 4394 Patients
Background: Biodegradable‐polymer (BP) drug‐eluting stents (DES) were developed to mitigate potential late adverse events related to persistent durable polymers in durable‐polymer (DP) DES; however, contemporary long‐term real‐world comparative data remain limited. Aims: We aimed to compare the 5‐year clinical outcomes of contemporary BP‐DES and DP‐DES in patients undergoing routine percutaneous coronary intervention (PCI). Methods: We analyzed consecutive patients undergoing PCI with second‐generation or newer DES at a single institution (2010–2021). Propensity scores were estimated using prespecified clinical, angiographic, and procedural covariates, and 1:1 nearest‐neighbor matching was performed. The primary endpoint was 5‐year target lesion failure (TLF: cardiac death, target vessel myocardial infarction [TV‐MI], or clinically driven target lesion revascularization [TLR]). Key secondary endpoints were 1‐year TLF, all‐cause mortality, and ARC‐2 definite or probable stent thrombosis. A prespecified 1‐year landmark analysis evaluated outcomes from 0 to 1 and 1 to 5 years. Results: After matching, 2197 pairs (4394 patients) were included. At 5 years, TLF occurred in 7.9% of BP‐DES and 7.9% of DP‐DES patients (HR 1.01, 95% CI 0.81–1.26; p = 0.936). No statistically significant differences were observed in secondary endpoints, including 1‐year TLF, individual TLF components, all‐cause mortality, or ARC‐2 definite or probable stent thrombosis. All‐cause mortality at 5 years was similar between groups (7.1% vs. 8.2%; HR 0.87, 95% CI 0.69–1.09; p = 0.213); however, in the 1–5‐year landmark period, mortality was numerically lower with BP‐DES (HR 0.73, 95% CI 0.53–1.00; nominal p = 0.047). No significant treatment‐by‐subgroup interactions were observed. Conclusions: In routine PCI using second‐generation or newer DES, BP‐DES and DP‐DES demonstrated comparable 5‐year TLF. The potential late survival signal with BP‐DES is hypothesis‐generating and should be interpreted cautiously given the observational design.
- 22 September 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Open AccessFive‐Year Clinical Outcomes of Biodegradable Versus Durable Polymer Drug‐Eluting Stents: A Propensity Score‐Matched Analysis of 4394 Patients
Background: Biodegradable‐polymer (BP) drug‐eluting stents (DES) were developed to mitigate potential late adverse events related to persistent durable polymers in durable‐polymer (DP) DES; however, contemporary long‐term real‐world comparative data remain limited. Aims: We aimed to compare the 5‐year clinical outcomes of contemporary BP‐DES and DP‐DES in patients undergoing routine percutaneous coronary intervention (PCI). Methods: We analyzed consecutive patients undergoing PCI with second‐generation or newer DES at a single institution (2010–2021). Propensity scores were estimated using prespecified clinical, angiographic, and procedural covariates, and 1:1 nearest‐neighbor matching was performed. The primary endpoint was 5‐year target lesion failure (TLF: cardiac death, target vessel myocardial infarction [TV‐MI], or clinically driven target lesion revascularization [TLR]). Key secondary endpoints were 1‐year TLF, all‐cause mortality, and ARC‐2 definite or probable stent thrombosis. A prespecified 1‐year landmark analysis evaluated outcomes from 0 to 1 and 1 to 5 years. Results: After matching, 2197 pairs (4394 patients) were included. At 5 years, TLF occurred in 7.9% of BP‐DES and 7.9% of DP‐DES patients (HR 1.01, 95% CI 0.81–1.26; p = 0.936). No statistically significant differences were observed in secondary endpoints, including 1‐year TLF, individual TLF components, all‐cause mortality, or ARC‐2 definite or probable stent thrombosis. All‐cause mortality at 5 years was similar between groups (7.1% vs. 8.2%; HR 0.87, 95% CI 0.69–1.09; p = 0.213); however, in the 1–5‐year landmark period, mortality was numerically lower with BP‐DES (HR 0.73, 95% CI 0.53–1.00; nominal p = 0.047). No significant treatment‐by‐subgroup interactions were observed. Conclusions: In routine PCI using second‐generation or newer DES, BP‐DES and DP‐DES demonstrated comparable 5‐year TLF. The potential late survival signal with BP‐DES is hypothesis‐generating and should be interpreted cautiously given the observational design.
- Open Access
- 1 January 2025
- Published by XMLink in Korean Circulation Journal
- Vol. 55 (6) , 497-508
Osfit™, a Novel Stent Designed for the Treatment of Coronary Ostial Lesions: Initial Clinical Experience and Intravascular Ultrasound Evaluation
Seo KW, et al. Korean Circ J. 2025 Feb;55:e30. https://doi.org/10.4070/kcj.2024.0256
- 1 January 2025
- Published by XMLink in Korean Circulation Journal
- Vol. 55 (6) , 497-508
Open AccessOsfit™, a Novel Stent Designed for the Treatment of Coronary Ostial Lesions: Initial Clinical Experience and Intravascular Ultrasound Evaluation
Seo KW, et al. Korean Circ J. 2025 Feb;55:e30. https://doi.org/10.4070/kcj.2024.0256
- Open Access
- 1 January 2024
- Published by XMLink in Korean Circulation Journal
- Vol. 54 (8) , 485-496
Discordance Between Angiographic Assessment and Fractional Flow Reserve or Intravascular Ultrasound in Intermediate Coronary Lesions: A Post-hoc Analysis of the FLAVOUR Trial
Lee JH, et al. Korean Circ J. 2024 Jun;54:e69. https://doi.org/10.4070/kcj.2024.0046
- 1 January 2024
- Published by XMLink in Korean Circulation Journal
- Vol. 54 (8) , 485-496
Open AccessDiscordance Between Angiographic Assessment and Fractional Flow Reserve or Intravascular Ultrasound in Intermediate Coronary Lesions: A Post-hoc Analysis of the FLAVOUR Trial
Lee JH, et al. Korean Circ J. 2024 Jun;54:e69. https://doi.org/10.4070/kcj.2024.0046
- 1 December 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 16 (12)
Clinical Outcomes of Deferred Lesions by IVUS Versus FFR-Guided Treatment Decision
BACKGROUND: There are limited data regarding the safety of deferral of percutaneous coronary intervention based on intravascular ultrasound (IVUS) findings. The current study sought to compare the prognosis between deferred lesions based on IVUS and fractional flow reserve (FFR)–guided treatment decision. METHODS: This study is a post hoc analysis of the FLAVOUR randomized trial (Fractional Flow Reserve and Intravascular Ultrasound for Clinical Outcomes in Patients With Intermediate Stenosis) that compared 2-year clinical outcomes between IVUS- and FFR-guided treatment decision on intermediate coronary artery lesions using predefined criteria. In both IVUS and FFR groups, vessels were classified into deferred or revascularized vessels, and patients were classified as those with or without deferred lesions. Vessel-oriented composite outcomes (cardiac death, target vessel myocardial infarction, or target vessel revascularization) in deferred vessels and patient-oriented composite outcomes (death, myocardial infarction, or any revascularization) in patients with deferred lesions were compared between the IVUS and FFR groups. RESULTS: A total of 1682 patients and 1820 vessels were analyzed, of which 922 patients and 989 vessels were deferred. At 2 years, there was no difference in the cumulative incidence of vessel-oriented composite outcomes in deferred vessels between IVUS (n=375) and FFR (n=614) groups (3.8% versus 4.1%; hazard ratio, 0.91 [95% CI, 0.47–1.75]; P =0.77). The risk of vessel-oriented composite outcomes was comparable between deferred and revascularized vessels following treatment decision by IVUS (3.8% versus 3.5%; hazard ratio, 1.09 [95% CI, 0.54–2.19]; P =0.81) and FFR (4.1% versus 3.6%; hazard ratio, 1.14 [95% CI, 0.56–2.32]; P =0.72). In comparison of patient-oriented composite outcomes in patients with deferred lesions, there was no significant difference between the IVUS (n=357) and FFR (n=565) groups (6.2% versus 5.9%; hazard ratio, 1.05 [95% CI, 0.61–1.80]; P =0.86). CONCLUSIONS: In patients with intermediate coronary artery stenosis, deferral of percutaneous coronary intervention based on IVUS-guided treatment decision showed comparable risk of clinical events with FFR-guided treatment decision. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02673424.
- 1 December 2023
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 16 (12)
Clinical Outcomes of Deferred Lesions by IVUS Versus FFR-Guided Treatment Decision
BACKGROUND: There are limited data regarding the safety of deferral of percutaneous coronary intervention based on intravascular ultrasound (IVUS) findings. The current study sought to compare the prognosis between deferred lesions based on IVUS and fractional flow reserve (FFR)–guided treatment decision. METHODS: This study is a post hoc analysis of the FLAVOUR randomized trial (Fractional Flow Reserve and Intravascular Ultrasound for Clinical Outcomes in Patients With Intermediate Stenosis) that compared 2-year clinical outcomes between IVUS- and FFR-guided treatment decision on intermediate coronary artery lesions using predefined criteria. In both IVUS and FFR groups, vessels were classified into deferred or revascularized vessels, and patients were classified as those with or without deferred lesions. Vessel-oriented composite outcomes (cardiac death, target vessel myocardial infarction, or target vessel revascularization) in deferred vessels and patient-oriented composite outcomes (death, myocardial infarction, or any revascularization) in patients with deferred lesions were compared between the IVUS and FFR groups. RESULTS: A total of 1682 patients and 1820 vessels were analyzed, of which 922 patients and 989 vessels were deferred. At 2 years, there was no difference in the cumulative incidence of vessel-oriented composite outcomes in deferred vessels between IVUS (n=375) and FFR (n=614) groups (3.8% versus 4.1%; hazard ratio, 0.91 [95% CI, 0.47–1.75]; P =0.77). The risk of vessel-oriented composite outcomes was comparable between deferred and revascularized vessels following treatment decision by IVUS (3.8% versus 3.5%; hazard ratio, 1.09 [95% CI, 0.54–2.19]; P =0.81) and FFR (4.1% versus 3.6%; hazard ratio, 1.14 [95% CI, 0.56–2.32]; P =0.72). In comparison of patient-oriented composite outcomes in patients with deferred lesions, there was no significant difference between the IVUS (n=357) and FFR (n=565) groups (6.2% versus 5.9%; hazard ratio, 1.05 [95% CI, 0.61–1.80]; P =0.86). CONCLUSIONS: In patients with intermediate coronary artery stenosis, deferral of percutaneous coronary intervention based on IVUS-guided treatment decision showed comparable risk of clinical events with FFR-guided treatment decision. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02673424.
- Open Access
- 15 September 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (37) , e35187
Sustained beneficial effect of β-blockers on clinical outcomes after discontinuation in patients with ST elevation myocardial infarction
Our previous study demonstrated that beneficial effect of β-blockers on clinical outcomes in patients with ST elevation myocardial infarction (STEMI). In clinical practice, β-blocker treatment is occasionally discontinued due to their side effect. The purpose of this study is to assess the impact of discontinuation of β-blockers on long-term clinical outcomes in patients with STEMI. We analyzed the data and clinical outcomes of 901 patients (716 males, 58 ± 13-year-old) STEMI patients who underwent successful primary percutaneous coronary intervention. At discharge of index STEMI, 598 patients were treated with β-blockers (491 males, 56 ± 12-year-old). After more than 1-month β-blocker treatment, β-blockers were stopped in 188 patients for any reason. We classified patients into continuation of β-blockers (410 patients, 56 ± 12-year-old) and discontinuation of β-blockers groups (188 patients, 57 ± 11-year-old) according to discontinuation of β-blockers. Occurrence of major adverse cardiovascular events (MACEs; death, recurrent MI and target vessel revascularization) during up to 10 years of follow-up was evaluated. Mean follow-up month was 56 ± 28 month. In 132 patients (22%), MACEs were occurred. The MACE-free survival rates in the 2 groups were not statistically different (log-rank P = .461). Adjusted hazard ratio (HR) of discontinuation of β-blockers for MACEs was 1.006 (95% confidence interval (CI) 0.701–1.445, P = .973; all cause of death, HR = 0.942, 95% CI = 0.547–1.622, P = .828; recurrent MI, HR = 0.476, 95% CI = 0.179–1.262, P = .136; target vessel revascularization, HR = 1.417, 95% CI = 0.865–2.321, P = .166). The MACE-free survival and survival rates of the non β-blockers treatment group was significantly worse than the discontinuation of β-blockers group (log-rank P = .003 and < 0.001, respectively). This study demonstrated that discontinuation of β-blockers was not associated with adverse cardiovascular outcomes after STEMI. The beneficial effect of β-blockers on clinical outcomes may persist in patients with initial β-blockers treatment at index STEMI.
- 15 September 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (37) , e35187
Open AccessSustained beneficial effect of β-blockers on clinical outcomes after discontinuation in patients with ST elevation myocardial infarction
Our previous study demonstrated that beneficial effect of β-blockers on clinical outcomes in patients with ST elevation myocardial infarction (STEMI). In clinical practice, β-blocker treatment is occasionally discontinued due to their side effect. The purpose of this study is to assess the impact of discontinuation of β-blockers on long-term clinical outcomes in patients with STEMI. We analyzed the data and clinical outcomes of 901 patients (716 males, 58 ± 13-year-old) STEMI patients who underwent successful primary percutaneous coronary intervention. At discharge of index STEMI, 598 patients were treated with β-blockers (491 males, 56 ± 12-year-old). After more than 1-month β-blocker treatment, β-blockers were stopped in 188 patients for any reason. We classified patients into continuation of β-blockers (410 patients, 56 ± 12-year-old) and discontinuation of β-blockers groups (188 patients, 57 ± 11-year-old) according to discontinuation of β-blockers. Occurrence of major adverse cardiovascular events (MACEs; death, recurrent MI and target vessel revascularization) during up to 10 years of follow-up was evaluated. Mean follow-up month was 56 ± 28 month. In 132 patients (22%), MACEs were occurred. The MACE-free survival rates in the 2 groups were not statistically different (log-rank P = .461). Adjusted hazard ratio (HR) of discontinuation of β-blockers for MACEs was 1.006 (95% confidence interval (CI) 0.701–1.445, P = .973; all cause of death, HR = 0.942, 95% CI = 0.547–1.622, P = .828; recurrent MI, HR = 0.476, 95% CI = 0.179–1.262, P = .136; target vessel revascularization, HR = 1.417, 95% CI = 0.865–2.321, P = .166). The MACE-free survival and survival rates of the non β-blockers treatment group was significantly worse than the discontinuation of β-blockers group (log-rank P = .003 and < 0.001, respectively). This study demonstrated that discontinuation of β-blockers was not associated with adverse cardiovascular outcomes after STEMI. The beneficial effect of β-blockers on clinical outcomes may persist in patients with initial β-blockers treatment at index STEMI.
- Open Access
- 26 September 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5658
Effect of Stenting Strategy on the Outcome in Patients with Non-Left Main Bifurcation Lesions
Previous studies have not compared outcomes between different percutaneous coronary intervention (PCI) strategies and lesion locations in non-left main (LM) bifurcation lesions. We enrolled 2044 patients from a multicenter registry with an LAD bifurcation lesion (n = 1551) or non-LAD bifurcation lesion (n = 493). The primary outcome was target lesion failure (TLF), a composite of cardiac death, myocardial infarction, and target lesion revascularization (TLR). During a median follow-up period of 38 months, non-LAD bifurcation lesions treated with the two-stent strategy, compared with the one-stent strategy, were associated with more frequent TLF (20.7% vs. 6.3%, p < 0.01), TLR (16.7% vs. 4.7%, p < 0.01), and target vessel revascularization (TVR; 18.2% vs. 6.3%, p < 0.01). There was no significant difference in outcome among LAD bifurcation lesions treated with different PCI strategies. The two-stent strategy was associated with a higher risk of TLF (adjusted HR 4.34, CI 1.93–9.76, p < 0.01), TLR (adjusted HR 4.30, CI 1.64–11.27, p < 0.01), and TVR (adjusted HR 5.07, CI 1.69–9.74, p < 0.01) in the non-LAD bifurcation lesions. The planned one-stent strategy is preferable to the two-stent strategy for the treatment of non-LAD bifurcation lesions.
- 26 September 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (19) , 5658
Open AccessEffect of Stenting Strategy on the Outcome in Patients with Non-Left Main Bifurcation Lesions
Previous studies have not compared outcomes between different percutaneous coronary intervention (PCI) strategies and lesion locations in non-left main (LM) bifurcation lesions. We enrolled 2044 patients from a multicenter registry with an LAD bifurcation lesion (n = 1551) or non-LAD bifurcation lesion (n = 493). The primary outcome was target lesion failure (TLF), a composite of cardiac death, myocardial infarction, and target lesion revascularization (TLR). During a median follow-up period of 38 months, non-LAD bifurcation lesions treated with the two-stent strategy, compared with the one-stent strategy, were associated with more frequent TLF (20.7% vs. 6.3%, p < 0.01), TLR (16.7% vs. 4.7%, p < 0.01), and target vessel revascularization (TVR; 18.2% vs. 6.3%, p < 0.01). There was no significant difference in outcome among LAD bifurcation lesions treated with different PCI strategies. The two-stent strategy was associated with a higher risk of TLF (adjusted HR 4.34, CI 1.93–9.76, p < 0.01), TLR (adjusted HR 4.30, CI 1.64–11.27, p < 0.01), and TVR (adjusted HR 5.07, CI 1.69–9.74, p < 0.01) in the non-LAD bifurcation lesions. The planned one-stent strategy is preferable to the two-stent strategy for the treatment of non-LAD bifurcation lesions.
- Open Access
- 14 May 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (19) , e25765
Five-year clinical outcomes of the first Korean-made sirolimus-eluting coronary stent with abluminal biodegradable polymer
This study evaluated the 5-year clinical outcomes of the Genoss DES, the first Korean-made sirolimus-eluting coronary stent with abluminal biodegradable polymer. We previously conducted the first-in-patient prospective, multicenter, randomized trial with a 1:1 ratio of patients using the Genoss DES and Promus Element stents; the angiographic and clinical outcomes of the Genoss DES stent were comparable to those of the Promus Element stent. The primary endpoint was major adverse cardiac events (MACE), which was a composite of death, myocardial infarction (MI), and target lesion revascularization (TLR) at 5 years. We enrolled 38 patients in the Genoss DES group and 39 in the Promus Element group. Thirty-eight patients (100%) from the Genoss DES group and 38 (97.4%) from the Promus Element group were followed up at 5 years. The rates of MACE (5.3% vs 12.8%, P = .431), death (5.3% vs 10.3%, P = .675), TLR (2.6% vs 2.6%, P = 1.000), and target vessel revascularization (TVR) (7.9% vs 2.6%, P = .358) at 5 years did not differ significantly between the groups. No TLR or target vessel revascularization was reported from years 1 to 5 after the index procedure, and no MI or stent thrombosis occurred in either group during 5 years. The biodegradable polymer Genoss DES and durable polymer Promus Element stents showed comparable low rates of MACE at the 5-year clinical follow-up.
- 14 May 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (19) , e25765
Open AccessFive-year clinical outcomes of the first Korean-made sirolimus-eluting coronary stent with abluminal biodegradable polymer
This study evaluated the 5-year clinical outcomes of the Genoss DES, the first Korean-made sirolimus-eluting coronary stent with abluminal biodegradable polymer. We previously conducted the first-in-patient prospective, multicenter, randomized trial with a 1:1 ratio of patients using the Genoss DES and Promus Element stents; the angiographic and clinical outcomes of the Genoss DES stent were comparable to those of the Promus Element stent. The primary endpoint was major adverse cardiac events (MACE), which was a composite of death, myocardial infarction (MI), and target lesion revascularization (TLR) at 5 years. We enrolled 38 patients in the Genoss DES group and 39 in the Promus Element group. Thirty-eight patients (100%) from the Genoss DES group and 38 (97.4%) from the Promus Element group were followed up at 5 years. The rates of MACE (5.3% vs 12.8%, P = .431), death (5.3% vs 10.3%, P = .675), TLR (2.6% vs 2.6%, P = 1.000), and target vessel revascularization (TVR) (7.9% vs 2.6%, P = .358) at 5 years did not differ significantly between the groups. No TLR or target vessel revascularization was reported from years 1 to 5 after the index procedure, and no MI or stent thrombosis occurred in either group during 5 years. The biodegradable polymer Genoss DES and durable polymer Promus Element stents showed comparable low rates of MACE at the 5-year clinical follow-up.
- Open Access
- 1 January 2019
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 49 (11) , 1010-1018
Lipid-Core Plaque Assessed by Near-Infrared Spectroscopy and Procedure Related Microvascular Injury
Yang HM, et al. Korean Circ J. 2018 Aug;49:e100. https://doi.org/10.4070/kcj.2019.0072
- 1 January 2019
- Published by The Korean Society of Cardiology in Korean Circulation Journal
- Vol. 49 (11) , 1010-1018
Open AccessLipid-Core Plaque Assessed by Near-Infrared Spectroscopy and Procedure Related Microvascular Injury
Yang HM, et al. Korean Circ J. 2018 Aug;49:e100. https://doi.org/10.4070/kcj.2019.0072
- Open Access
- 1 January 2018
- Published by XMLink in Korean Circulation Journal
- Vol. 48 (1) , 16-23
Ischemia-based Coronary Revascularization: Beyond Anatomy and Fractional Flow Reserve
Lim HS, et al. Korean Circ J. 2016 Sep;48:e1. https://doi.org/10.4070/kcj.2017.0177
- 1 January 2018
- Published by XMLink in Korean Circulation Journal
- Vol. 48 (1) , 16-23
Open AccessIschemia-based Coronary Revascularization: Beyond Anatomy and Fractional Flow Reserve
Lim HS, et al. Korean Circ J. 2016 Sep;48:e1. https://doi.org/10.4070/kcj.2017.0177
- Open Access
- 1 January 2018
- Published by XMLink in Korean Circulation Journal
- Vol. 48 (1) , 91-93
Extrinsic Compression of the Left Main Coronary Artery by a Huge Aortic Arch Aneurysm Mimicking Acute Coronary Syndrome
Shin JS, et al. Korean Circ J. 2016 Sep;48:e13. https://doi.org/10.4070/kcj.2017.0313
- 1 January 2018
- Published by XMLink in Korean Circulation Journal
- Vol. 48 (1) , 91-93
Open AccessExtrinsic Compression of the Left Main Coronary Artery by a Huge Aortic Arch Aneurysm Mimicking Acute Coronary Syndrome
Shin JS, et al. Korean Circ J. 2016 Sep;48:e13. https://doi.org/10.4070/kcj.2017.0313